Development and pilot of a prescription drug monitoring program and communication intervention for pharmacists.

Communication Community pharmacist Opioid safety PDMP Toolkit Training

Journal

Research in social & administrative pharmacy : RSAP
ISSN: 1934-8150
Titre abrégé: Res Social Adm Pharm
Pays: United States
ID NLM: 101231974

Informations de publication

Date de publication:
10 2020
Historique:
received: 07 06 2019
revised: 29 12 2019
accepted: 29 12 2019
pubmed: 19 1 2020
medline: 15 7 2021
entrez: 19 1 2020
Statut: ppublish

Résumé

Pharmacists' role in addressing the opioid crisis continues to expand, but lack of training specifically related to standardized prescription drug monitoring program (PDMP) use and communication strategies for provider and patient interactions remains a significant issue. We developed the Resources Encouraging Safe Prescription Opioid and Naloxone Dispensing (RESPOND) Toolkit to enhance community pharmacists' understanding of their role in addressing opioid safety; improve integration of PDMP into daily workflow; and enhance communication between pharmacists, prescribers, and patients. To describe the development of RESPOND Toolkit and summarize findings from initial pilot testing. RESPOND development was informed by focus groups with patients, prescribers, and pharmacists and an external advisory committee. Materials developed include a patient screening & communication algorithm, a provider communication checklist and an online continuing education course with three distinct modules. The RESPOND Toolkit was pilot tested in six community pharmacies in Oregon across two 6-month intervention phases. Pilot data collection included a pre-post intervention survey, pre-post knowledge assessment quizzes within the online course, and post-intervention semi-structured interviews. Interview feedback informed revisions after each phase to shape the final content, flow, and delivery of RESPOND. Sixteen of 21 pharmacists completed the online training, revealing a large, significant effect on knowledge gain across the three training modules (pre-score 57, post-score 84; p < 0.001; Cohen's d = 1.85). Of these participants, 10 also completed the baseline and post intervention survey and showed non-significant moderate improvements in knowledge, perceived behavioral control, and self-efficacy to address opioid safety issues. The RESPOND Toolkit has promise as an effective and scalable approach to providing community pharmacist-tailored training, especially in the areas of effective communication and workflow integration, to promote behavioral shifts supporting opioid safety for patients. Further development and testing in a larger sample is warranted.

Sections du résumé

BACKGROUND
Pharmacists' role in addressing the opioid crisis continues to expand, but lack of training specifically related to standardized prescription drug monitoring program (PDMP) use and communication strategies for provider and patient interactions remains a significant issue. We developed the Resources Encouraging Safe Prescription Opioid and Naloxone Dispensing (RESPOND) Toolkit to enhance community pharmacists' understanding of their role in addressing opioid safety; improve integration of PDMP into daily workflow; and enhance communication between pharmacists, prescribers, and patients.
OBJECTIVE
To describe the development of RESPOND Toolkit and summarize findings from initial pilot testing.
METHODS
RESPOND development was informed by focus groups with patients, prescribers, and pharmacists and an external advisory committee. Materials developed include a patient screening & communication algorithm, a provider communication checklist and an online continuing education course with three distinct modules. The RESPOND Toolkit was pilot tested in six community pharmacies in Oregon across two 6-month intervention phases. Pilot data collection included a pre-post intervention survey, pre-post knowledge assessment quizzes within the online course, and post-intervention semi-structured interviews. Interview feedback informed revisions after each phase to shape the final content, flow, and delivery of RESPOND.
RESULTS
Sixteen of 21 pharmacists completed the online training, revealing a large, significant effect on knowledge gain across the three training modules (pre-score 57, post-score 84; p < 0.001; Cohen's d = 1.85). Of these participants, 10 also completed the baseline and post intervention survey and showed non-significant moderate improvements in knowledge, perceived behavioral control, and self-efficacy to address opioid safety issues.
CONCLUSION
The RESPOND Toolkit has promise as an effective and scalable approach to providing community pharmacist-tailored training, especially in the areas of effective communication and workflow integration, to promote behavioral shifts supporting opioid safety for patients. Further development and testing in a larger sample is warranted.

Identifiants

pubmed: 31953112
pii: S1551-7411(19)30580-7
doi: 10.1016/j.sapharm.2019.12.023
pii:
doi:

Substances chimiques

Naloxone 36B82AMQ7N

Types de publication

Journal Article Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

1422-1430

Subventions

Organisme : AHRQ HHS
ID : R18 HS024227
Pays : United States

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Auteurs

Lindsey Alley (L)

Comagine Health, 650 NE Holladay St., Suite 1700, Portland, OR, 97232, USA.

Kevin Novak (K)

Comagine Health, 650 NE Holladay St., Suite 1700, Portland, OR, 97232, USA.

Tyler Havlin (T)

Comagine Health, 650 NE Holladay St., Suite 1700, Portland, OR, 97232, USA.

Adriane N Irwin (AN)

Oregon State University, College of Pharmacy, 2730 SW Moody Ave., Mailcode: CL5CP, Portland, OR, 97201, USA.

Jody Carson (J)

Comagine Health, 650 NE Holladay St., Suite 1700, Portland, OR, 97232, USA.

Kirbee Johnston (K)

Oregon State University, College of Pharmacy, 2730 SW Moody Ave., Mailcode: CL5CP, Portland, OR, 97201, USA.

Nicole O'Kane (N)

Comagine Health, 650 NE Holladay St., Suite 1700, Portland, OR, 97232, USA.

Daniel M Hartung (DM)

Oregon State University, College of Pharmacy, 2730 SW Moody Ave., Mailcode: CL5CP, Portland, OR, 97201, USA. Electronic address: hartungd@ohsu.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH